Similar Papers

Paper Title
Journal
Date
Author
Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Iñigo Bermejo ... Matt Stevenson
PharmacoEconomics | VOL. 35
Iñigo Bermejo, et. al.Iñigo Bermejo ... Matt Stevenson
26 May 2017
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Iñigo Bermejo ... Shijie Ren
PharmacoEconomics | VOL. 36
Iñigo Bermejo, et. al.Iñigo Bermejo ... Shijie Ren
08 Jun 2018
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Shijie Ren ... Emma Hock
PharmacoEconomics | VOL. 37
Shijie Ren, et. al.Shijie Ren ... Emma Hock
13 Dec 2018
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mohamed N M T Al Khayat ... Nigel Armstrong
PharmacoEconomics | VOL. 41
Mohamed N M T Al Khayat, et. al.Mohamed N M T Al Khayat ... Nigel Armstrong
09 Feb 2023
View more papers

More From: Value in Health

Paper Title
Journal
Date
Author
Table of Contents
-
Value in Health | VOL. -
--
01 Jan 2025
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force
Siobhan Botwright ... Yot Teerawattananon
Value in Health | VOL. -
Siobhan Botwright, et. al.Siobhan Botwright ... Yot Teerawattananon
01 Jan 2025
Editorial Board
-
Value in Health | VOL. -
--
01 Jan 2025
OP1 Electroencephalogram (EEG) Cup Electrode Application: A Multicenter Prospective Study
D Hoffman ... C Cool
Value in Health | VOL. 27
D Hoffman, et. al.D Hoffman ... C Cool
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.